Mitoconix Bio, an innovative Israeli startup bred by Israel’s only life science incubator, FutuRx, has recently raised $20 million to develop a promising drug for the treatment of Huntington’s disease and other neurodegenerative disorders, as reported by the Times of Israel. Both Mitoconix Bio and FutuRx are clients of GT’s Barry Schindler, co-chair of Greenberg … Continue Reading